Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77


Allograft for Myeloma: Examining Pieces of the Jigsaw Puzzle.

Malek E, El-Jurdi N, Kröger N, de Lima M.

Front Oncol. 2017 Dec 11;7:287. doi: 10.3389/fonc.2017.00287. eCollection 2017. Review.


ATG in allogeneic stem cell transplantation: standard of care in 2017? Counterpoint.

Kekre N, Antin JH.

Blood Adv. 2017 Mar 28;1(9):573-576. doi: 10.1182/bloodadvances.2016001552. eCollection 2017 Mar 28.


ATG in allogeneic stem cell transplantation: standard of care in 2017? Point.

Bacigalupo A.

Blood Adv. 2017 Mar 28;1(9):569-572. doi: 10.1182/bloodadvances.2016001560. eCollection 2017 Mar 28.


Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide.

Kasamon YL, Ambinder RF, Fuchs EJ, Zahurak M, Rosner GL, Bolaños-Meade J, Levis MJ, Gladstone DE, Huff CA, Swinnen LJ, Matsui WH, Borrello I, Brodsky RA, Jones RJ, Luznik L.

Blood Adv. 2017;1(4):288-292. doi: 10.1182/bloodadvances.2016002766. Epub 2017 Jan 6.


Dissecting the mechanisms involved in anti-human T-lymphocyte immunoglobulin (ATG)-induced tolerance in the setting of allogeneic stem cell transplantation - potential implications for graft versus host disease.

Beider K, Naor D, Voevoda V, Ostrovsky O, Bitner H, Rosenberg E, Varda-Bloom N, Marcu-Malina V, Canaani J, Danilesko I, Shimoni A, Nagler A.

Oncotarget. 2017 Oct 11;8(53):90748-90765. doi: 10.18632/oncotarget.21797. eCollection 2017 Oct 31.


Immune reconstitution and outcomes after conditioning with anti-thymocyte-globulin in unrelated cord blood transplantation; the good, the bad, and the ugly.

de Koning C, Admiraal R, Nierkens S, Boelens JJ.

Stem Cell Investig. 2017 May 16;4:38. doi: 10.21037/sci.2017.05.02. eCollection 2017. Review.


HLA-C KIR-Ligands Determine the Impact of Anti-Thymocyte Globulin (ATG) on Graft versus Host and Graft versus Leukemia Effects Following Hematopoietic Stem Cell Transplantation.

Clausen J, Böhm A, Straßl I, Stiefel O, Buxhofer-Ausch V, Machherndl-Spandl S, König J, Schmidt S, Steitzer H, Danzer M, Kasparu H, Weltermann A, Nachbaur D.

Biomedicines. 2017 Mar 28;5(2). pii: E13. doi: 10.3390/biomedicines5020013.


Ex vivo T-cell depletion in allogeneic hematopoietic stem cell transplant: past, present and future.

Saad A, Lamb LS.

Bone Marrow Transplant. 2017 Sep;52(9):1241-1248. doi: 10.1038/bmt.2017.22. Epub 2017 Mar 20. Review.


Alemtuzumab as graft-versus-host disease (GVHD) prophylaxis strategy in a developing country: lower rate of acute GVHD, increased risk of cytomegalovirus reactivation.

Resende CB, Rezende BM, Bernardes PT, Teixeira GM, Teixeira MM, Pinho V, Bittencourt H.

Braz J Med Biol Res. 2017 Feb 9;50(2):e5566. doi: 10.1590/1414-431X20165566.


Meta-analysis of the actions of antithymocyte globulin in patients undergoing allogeneic hematopoietic cell transplantation.

Yuan J, Pei R, Su W, Cao J, Lu Y.

Oncotarget. 2017 Feb 14;8(7):10871-10882. doi: 10.18632/oncotarget.14719.


Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Baron F, Mohty M, Blaise D, Socié G, Labopin M, Esteve J, Ciceri F, Giebel S, Gorin NC, Savani BN, Schmid C, Nagler A.

Haematologica. 2017 Feb;102(2):224-234. doi: 10.3324/haematol.2016.148510. Epub 2016 Dec 7. Review.


Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, Löwenberg B, Bloomfield CD.

Blood. 2017 Jan 26;129(4):424-447. doi: 10.1182/blood-2016-08-733196. Epub 2016 Nov 28. Review.


Classification systems for chronic graft-versus-host disease.

Lee SJ.

Blood. 2017 Jan 5;129(1):30-37. doi: 10.1182/blood-2016-07-686642. Epub 2016 Nov 7. Review.


Planes, Trains, and Automobiles: Perspectives on CAR T Cells and Other Cellular Therapies for Hematologic Malignancies.

Gill S.

Curr Hematol Malig Rep. 2016 Aug;11(4):318-25. doi: 10.1007/s11899-016-0330-5. Review.


Failure to effectively treat chronic graft-versus-host disease: a strong call for prevention.

Bacigalupo A, Sica S, van Lint MT.

Haematologica. 2016 May;101(5):e214-5. doi: 10.3324/haematol.2015.138040. No abstract available.


Nonmyeloablative allogeneic hematopoietic cell transplantation.

Storb R, Sandmaier BM.

Haematologica. 2016 May;101(5):521-30. doi: 10.3324/haematol.2015.132860. Review.


Prognostic Factors on the Graft-versus-Host Disease-Free and Relapse-Free Survival after Adult Allogeneic Hematopoietic Stem Cell Transplantation.

Liu YC, Chien SH, Fan NW, Hu MH, Gau JP, Liu CJ, Yu YB, Hsiao LT, Chiou TJ, Tzeng CH, Chen PM, Liu JH.

Stem Cells Int. 2016;2016:5143071. doi: 10.1155/2016/5143071. Epub 2016 Mar 30.


Impact of early CMV reactivation in cord blood stem cell recipients in the current era.

Ramanathan M, Teira P, Battiwalla M, Barrett J, Ahn KW, Chen M, Green J, Laughlin M, Lazarus HM, Marks D, Saad A, Seftel M, Saber W, Savani B, Waller EK, Wingard J, Auletta JJ, Lindemans CA, Boeckh M, Riches ML.

Bone Marrow Transplant. 2016 Aug;51(8):1113-20. doi: 10.1038/bmt.2016.89. Epub 2016 Apr 4.


Circulating T follicular helper cells with increased function during chronic graft-versus-host disease.

Forcade E, Kim HT, Cutler C, Wang K, Alho AC, Nikiforow S, Ho VT, Koreth J, Armand P, Alyea EP, Blazar BR, Soiffer RJ, Antin JH, Ritz J.

Blood. 2016 May 19;127(20):2489-97. doi: 10.1182/blood-2015-12-688895. Epub 2016 Mar 4.

Supplemental Content

Support Center